About this trial
Septic shock is one of the leading causes of death in patients admitted to the intensive care unit (ICU). Acute kidney injury (AKI) occurs in almost 50% of septic patients and is associated with significant mortality. Progression to the last stage (KDIGO stage 3) of AKI is an important step in the disease, as it usually requires initiation of RRT. Renal biomarkers are unable to accurately identify those patients who will progress to severe AKI (KDIGO 3). However, identification of patients at risk of progression to severe AKI could help the clinician to initiate optimal therapy including RRT. A new urine test, the Nephrocheck™ corresponding to the product of the urinary concentrations of 2 markers of renal tubule injury (TIMP2 and IGFBP7) has been validated. The Investigator have already performed two previous studies including septic shock patients (AKICHECK and BIOOCHECK). those previous datas will be reanalysed to examine whether the new urinary biomarkers TIMP2 and IGFBP7 can predict progression within 24 hours and 72 hours from mild and moderate (KDIGO 1 or 2) to severe AKI (KDIGO 3) in patients with septic shock.
-All the datas required will be collected from two previous studies (AKICHECK and BIOCHECK) performed in 3 centers: Amiens medical ICU, Melun medico surgical ICU and Montpellier Medical ICU.
Eligibility criteria
Qualifiers
Age 18 or over
Septic shock (according to Bone's criteria) within 4 hours of introduction of catecholamines
AKI, characterized by a KDIGO score ≥ 1
Social security coverage
Disqualifiers
AKI requiring emergency RRT (in the critical care physician's opinion).
Anuria
Stage 4-5 chronic kidney failure with a GFR below 30 ml/min.
Rapidly progressing renal disorders (glomerulonephritis, HUS, blockage, etc.)
Trial design
Treatments tested in this trial
- Nephrocheck test